Literature DB >> 11313702

Bcl-2 induces cyclin D1 promoter activity in human breast epithelial cells independent of cell anchorage.

H M Lin1, Y J Lee, G Li, R G Pestell, H R Kim.   

Abstract

Cyclin D1 expression is co-regulated by growth factor and cell adhesion signaling. Cell adhesion to the extracellular matrix activates focal adhesion kinase (FAK), which is essential for cyclin D1 expression. Upon the loss of cell adhesion, cyclin D1 expression is downregulated, followed by apoptosis in normal epithelial cells. Since bcl-2 prevents apoptosis induced by the loss of cell adhesion, we hypothesized that bcl-2 induces survival signaling complementary to cell adhesion-mediated gene regulation. In the present study, we investigated the role of bcl-2 on FAK activity and cyclin D1 expression. We found that bcl-2 overexpression induces cyclin D1 expression in human breast epithelial cell line MCF10A independent of cell anchorage. Increased cyclin D1 expression in stable bcl-2 transfectants is not related to bcl-2-increased G1 duration, but results from cyclin D1 promoter activation. Transient transfection studies confirmed anchorage-independent bcl-2 induction of cyclin D1 promoter activity in human breast epithelial cell lines (MCF10A, BT549, and MCF-7). We provide evidence that bcl-2 induction of cyclin D1 expression involves constitutive activation of focal adhesion kinase, regardless of cell adhesion. The present study suggests a potential oncogenic activity for bcl-2 through cyclin D1 induction, and provides an insight into the distinct proliferation-independent pathway leading to increased cyclin D1 expression in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313702     DOI: 10.1038/sj.cdd.4400770

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  9 in total

1.  Flavin Oxidase-Induced ROS Generation Modulates PKC Biphasic Effect of Resveratrol on Endothelial Cell Survival.

Authors:  Anna Maria Posadino; Roberta Giordo; Annalisa Cossu; Gheyath K Nasrallah; Abdullah Shaito; Haissam Abou-Saleh; Ali H Eid; Gianfranco Pintus
Journal:  Biomolecules       Date:  2019-05-30

2.  Expression of paxillin in laryngeal squamous cell carcinoma and its prognostic value.

Authors:  Lianqing Li; Jing Wang; Lei Gao; Lili Gong
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

3.  BCL2 interaction with actin in vitro may inhibit cell motility by enhancing actin polymerization.

Authors:  Hengning Ke; Jennifer Y Zhang; Steven K Akiyama; John E French
Journal:  Cell Adh Migr       Date:  2011-01-01       Impact factor: 3.405

4.  Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14).

Authors:  Nina Nguyen; Sana Chaudhry; Tulasigeri M Totiger; Robert Diaz; Evan Roberts; Skye Montoya; Gabriel Pardo; Alejandro Pardo; Jumana Afaghani; Maurizio Affer; Jacob Jahn; Terrence Bradley; Francesco Maura; Dickran Kazandjian; Daniel Bilbao; Jennifer Chapman; Ola Landgren; James Hoffman; Justin Taylor
Journal:  NPJ Precis Oncol       Date:  2022-10-19

5.  Diverse roles for the paxillin family of proteins in cancer.

Authors:  Nicholas O Deakin; Jeanine Pignatelli; Christopher E Turner
Journal:  Genes Cancer       Date:  2012-05

6.  Microarray and pathway analysis reveals decreased CDC25A and increased CDC42 associated with slow growth of BCL2 overexpressing immortalized breast cell line.

Authors:  Jacquelyn M Long; Charles W Bell; W Samuel Fagg; Mary E Kushman; Kevin G Becker; James A McCubrey; Mary A Farwell
Journal:  Cell Cycle       Date:  2008-10-08       Impact factor: 4.534

7.  Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.

Authors:  Francesco Marampon; Giovanni Gravina; Xiaoming Ju; Antonella Vetuschi; Roberta Sferra; Mathew C Casimiro; Simona Pompili; Claudio Festuccia; Alessandro Colapietro; Eugenio Gaudio; Ernesto Di Cesare; Vincenzo Tombolini; Richard G Pestell
Journal:  Oncotarget       Date:  2016-02-02

Review 8.  FAK and paxillin, two potential targets in pancreatic cancer.

Authors:  Rajani Kanteti; Surinder K Batra; Frances E Lennon; Ravi Salgia
Journal:  Oncotarget       Date:  2016-05-24

9.  Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer.

Authors:  Ki-Tae Hwang; Young A Kim; Jongjin Kim; Hyeon Jeong Oh; Jeong Hwan Park; In Sil Choi; Jin Hyun Park; Sohee Oh; Ajung Chu; Jong Yoon Lee; Kyu Ri Hwang
Journal:  Sci Rep       Date:  2021-06-07       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.